Viking Therapeutics (VKTX) News Today $34.94 +0.89 (+2.61%) Closing price 04:00 PM EasternExtended Trading$35.02 +0.09 (+0.24%) As of 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Why this Weight-Loss Drug Stock Could Gain 200%January 23 at 7:38 AM | barrons.comThis Biotech Stock Soared 116% in 2024, but Is It a Buy in 2025?January 22 at 4:10 AM | fool.comWhat's next for Viking Therapeutics? Here's how the company can scale up.January 21 at 4:06 PM | marketwatch.comBillionaire Sold Palantir and Is Buying This Stock That Could Soar 237%, According to a Wall Street ExpertJanuary 21 at 3:15 PM | 247wallst.comViking Therapeutics’ Clinical Advancements and Strategic Partnerships Boost Buy RatingJanuary 21 at 2:02 PM | markets.businessinsider.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Bought by Royal Fund Management LLCRoyal Fund Management LLC grew its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 246.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 44,182 shares of the biotechnology company'January 21 at 6:59 AM | marketbeat.comViking Therapeutics: The Turning Point Is Not Here YetJanuary 20 at 4:56 PM | seekingalpha.comViking Therapeutics (NASDAQ:VKTX) Given Buy Rating at HC WainwrightJanuary 20 at 2:20 AM | americanbankingnews.comViking Therapeutics (NASDAQ:VKTX) Shares Down 4.8% - Here's WhyViking Therapeutics (NASDAQ:VKTX) Trading Down 4.8% - What's Next?January 18, 2025 | marketbeat.comShelton Wealth Management LLC Makes New Investment in Viking Therapeutics, Inc. (NASDAQ:VKTX)Shelton Wealth Management LLC purchased a new position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 22,199 shares of the biotechnology company'sJanuary 18, 2025 | marketbeat.comNovo Nordisk data boosts H.C. Wainwright confidence in Viking’s potentialJanuary 17, 2025 | markets.businessinsider.comViking Therapeutics’ VK2735: A Promising Contender in the Weight-Loss Market with Superior Efficacy ProfileJanuary 17, 2025 | markets.businessinsider.comViking Therapeutics (NASDAQ:VKTX) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $102.00 target price on shares of Viking Therapeutics in a research note on Friday.January 17, 2025 | marketbeat.comWhy Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped TodayJanuary 17, 2025 | fool.comViking Therapeutics (NASDAQ:VKTX) Sees Strong Trading Volume - What's Next?Viking Therapeutics (NASDAQ:VKTX) Sees Unusually-High Trading Volume - Here's WhyJanuary 16, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Down 4.8% - Here's What HappenedViking Therapeutics (NASDAQ:VKTX) Shares Down 4.8% - Should You Sell?January 16, 2025 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTXJanuary 14, 2025 | prnewswire.comWhy Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on TuesdayJanuary 14, 2025 | fool.comViking Therapeutics (NASDAQ:VKTX) Sees Large Volume Increase - Still a Buy?Viking Therapeutics (NASDAQ:VKTX) Sees Unusually-High Trading Volume - Still a Buy?January 14, 2025 | marketbeat.comInternational Assets Investment Management LLC Reduces Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)International Assets Investment Management LLC trimmed its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 98.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 18,276 shares ofJanuary 10, 2025 | marketbeat.comPositive Buy Rating on Viking Therapeutics Driven by Promising VK2735 Program AdvancesJanuary 9, 2025 | markets.businessinsider.comViking Therapeutics: Strategic Positioning and Promising Development of Oral 2735 Drive Buy RatingJanuary 9, 2025 | markets.businessinsider.com3 Mid-Cap Stocks That Could Take Off in 2025January 9, 2025 | fool.comPositive Outlook for Viking Therapeutics Amid Promising Trial DevelopmentsJanuary 8, 2025 | markets.businessinsider.comViking Therapeutics’ oral-2735 could differentiate asset, says JPMorganJanuary 8, 2025 | markets.businessinsider.comViking Therapeutics initiates Phase 2 VENTURE-oral dosing trial of VK2735January 8, 2025 | markets.businessinsider.comViking Therapeutics’ Promising Phase 2 Trial and Competitive Edge Justify Buy RatingJanuary 8, 2025 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTXJanuary 8, 2025 | prnewswire.comViking Therapeutics (NASDAQ:VKTX) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $102.00 target price on shares of Viking Therapeutics in a research report on Wednesday.January 8, 2025 | marketbeat.comViking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with ObesityJanuary 8, 2025 | prnewswire.comViking Therapeutics, Inc. (VKTX) Stock Sinks As Market Gains: What You Should KnowJanuary 7, 2025 | msn.comViking Therapeutics, Inc. (NASDAQ:VKTX) CFO Sells $2,150,709.75 in StockJanuary 7, 2025 | insidertrades.comViking Therapeutics, Inc. (NASDAQ:VKTX) Receives Consensus Recommendation of "Buy" from AnalystsShares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) have earned a consensus recommendation of "Buy" from the thirteen research firms that are currently covering the company, Marketbeat Ratings reports. Eleven equities research analysts have rated the stock with a buy rating and twoJanuary 7, 2025 | marketbeat.comInsider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) CFO Sells 50,309 Shares of StockViking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) CFO Greg Zante sold 50,309 shares of Viking Therapeutics stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $42.75, for a total value of $2,150,709.75. Following the transaction, the chief financial officer now directly owns 165,259 shares in the company, valued at $7,064,822.25. The trade was a 23.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.January 6, 2025 | marketbeat.comInsider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) COO Sells 54,215 Shares of StockViking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) COO Marianna Mancini sold 54,215 shares of the company's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $42.75, for a total transaction of $2,317,691.25. Following the completion of the transaction, the chief operating officer now owns 374,134 shares in the company, valued at approximately $15,994,228.50. This trade represents a 12.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.January 6, 2025 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) CEO Brian Lian Sells 194,490 SharesViking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) CEO Brian Lian sold 194,490 shares of the firm's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $42.75, for a total transaction of $8,314,447.50. Following the completion of the transaction, the chief executive officer now directly owns 2,366,570 shares of the company's stock, valued at $101,170,867.50. This represents a 7.59 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.January 6, 2025 | marketbeat.comViking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | prnewswire.com1 Under-the-Radar Stock to Buy Before It Soars by 156%, According to Select Wall Street AnalystsJanuary 6, 2025 | fool.comWhy Viking Therapeutics Stock Plummeted by 24% in DecemberJanuary 4, 2025 | fool.comViking Therapeutics among potential buyout candidates: OppenheimerJanuary 3, 2025 | seekingalpha.comShould You Buy the Dip on This High-Flying Stock?January 3, 2025 | fool.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTXJanuary 2, 2025 | prnewswire.com3 Stocks That Could Be Monster Winners in 2025December 29, 2024 | fool.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTXDecember 27, 2024 | prnewswire.comWill Viking Therapeutics, Inc. (VKTX) Make You Rich In 2025?December 24, 2024 | insidermonkey.comViking Therapeutics (NASDAQ:VKTX) Trading Down 0.1% - Here's What HappenedViking Therapeutics (NASDAQ:VKTX) Trading Down 0.1% - Should You Sell?December 24, 2024 | marketbeat.comPrincipal Financial Group Inc. Acquires 136,729 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)Principal Financial Group Inc. raised its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 29.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 593,528 shares of the biotechnology comDecember 24, 2024 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Shares Down 1.3% - Should You Sell?Viking Therapeutics (NASDAQ:VKTX) Trading Down 1.3% - Here's What HappenedDecember 23, 2024 | marketbeat.comIs Viking Therapeutics, Inc. (VKTX) the Best Performing Biotech Stock in 2024?December 23, 2024 | insidermonkey.comStocks on Sale: Novo Nordisk, Viking Therapeutics, Nike, and BitcoinDecember 23, 2024 | baystreet.ca Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address VKTX Media Mentions By Week VKTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VKTX News Sentiment▼0.390.62▲Average Medical News Sentiment VKTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VKTX Articles This Week▼1716▲VKTX Articles Average Week Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Summit Therapeutics News Today Genmab A/S News Today Viatris News Today Intra-Cellular Therapies News Today Moderna News Today Dr. Reddy's Laboratories News Today Catalent News Today Sarepta Therapeutics News Today Vaxcyte News Today Qiagen News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VKTX) was last updated on 1/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
